An African woman mixes chemicals in the laboratory of a state-of-the-art pharmaceutical manufacturing plant in Kampala, Uganda. The site manufactures and sells combination therapy antiretroviral and antimalarial drugs that have proven to be most effective in combating HIV/AIDS and Malaria. These diseases are two of Africa’s greatest challenges.

...

Amanda Castro

By Amanda Castro

Associate News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A Utah biotech startup says it has grown functional human sperm in a lab and used it to create early embryos—a development that, if validated, could dramatically expand options for men with severe infertility. The company, Paterna Biosciences, told WIRED it has successfully guided sperm‑forming stem cells through the full maturation process in vitro, a milestone researchers have pursued for decades.

The advance is still in its earliest stages. The findings have not been peer‑reviewed, independently replicated, or cleared for any clinical use. But Paterna’s projected timeline—with potential pregnancy‑initiation trials as soon as next year—is far faster than what many reproductive scientists have previously considered feasible.

Early‑Stage Results, Not Approved for Patients

Paterna’s announcement remains preliminary. No scientific paper has been published, and no outside lab has yet verified the results. Experts caution that the work must undergo rigorous genetic, developmental, and safety testing before it can be used in fertility clinics.

Read More on News

Still, the company’s claims represent a significant step toward in vitro spermatogenesis, the long‑sought goal of producing fully functional human sperm outside the body. Scientists have achieved this in mice—most notably in a landmark 2011 study from Japan—but translating the process to humans has proven far more complex.

A woman mixes chemicals in the laboratory of a state-of-the-art pharmaceutical manufacturing plant in Kampala, Uganda. The site manufactures and sells combination therapy antiretroviral and antimalarial drugs that have proven to be most effective in combating HIV/AIDS and malaria, diseases that are among Africa's greatest challenges.

...

Paterna Says It Has Grown Human Sperm Entirely Outside the Body

Paterna’s method begins with a small biopsy of testicular tissue. From that sample, researchers isolate spermatogonial stem cells, the starting cells that eventually become mature sperm. Using computational modeling, the team mapped the molecular signals required at each stage of sperm development and tested combinations of growth factors until the cells progressed through meiosis and developed the characteristic head‑and‑tail structure.

CEO Dr. Alexander Pastuszak, a urologist and University of Utah professor, told Newsweek that the company’s results represent a turning point for patients who have been told they have no options left.

“As a physician, I've sat across from far too many men and their partners and told them there's nothing more medicine can do: no sperm, poor sperm quality, repeated IVF failures,” Pastuszak said in a statement provided to Newsweek. “For millions of families around the world, those words are devastating. That's exactly why we built Paterna.”

He added that the company’s early results show lab‑grown sperm that appear structurally normal and capable of fertilizing eggs.

“We successfully grew functional human sperm from their starting cells, entirely outside the human body, and then we proved they work,” he said. “Our in vitro‑derived sperm fertilized human eggs and formed embryos. To our knowledge, this has never been done before in human history.”

Pastuszak said the achievement reflects “years of rigorous science” and could mark “the beginning of a new option” for men who have been told they have none.

Long‑Sought Goal in Reproductive Science

Producing human sperm in vitro—known as in vitro spermatogenesis—has been a major scientific challenge. A Japanese team first produced viable mouse sperm in 2011, but translating the process to humans has proven far more complex. A French company, Kallistem, claimed success in 2015, but outside experts questioned whether the sperm were fully developed and capable of fertilization.

Paterna’s claim goes further by reporting not only mature sperm but embryos created using those sperm, a key functional test.

Larry Lipshultz, a urologist at Baylor College of Medicine who is not affiliated with Paterna, told WIRED the work would be “huge” if validated, noting that researchers have long struggled to identify the precise growth factors needed to complete sperm development outside the body.

Potential Lifeline for Men With No Sperm

Roughly 10 percent to 15 percent of infertile men produce no sperm at all, leaving them with few or no options for biological parenthood. Many still possess sperm‑forming stem cells, but their testicular environment prevents those cells from maturing.

Paterna believes its technique could bypass that barrier by recreating a healthy developmental environment in the lab. The company says it has generated sperm from dozens of tissue samples and aims to produce thousands of sperm from a single biopsy.

For now, the only option for these men is an invasive surgical retrieval procedure that often fails to locate viable sperm. Experts say a reliable lab‑based alternative would be transformative.

Even if the science holds up, affordability may limit access, however. Fertility treatments in the U.S. are rarely covered by insurance, and Paterna expects its procedure to cost $5,000 to $12,000, not including IVF.

Dr. Justin Dubin, a urologist at Baptist Health Miami Cancer Institute, told WIRED that cost remains one of the biggest barriers in fertility care.

“We’re coming up with so many amazing options in fertility care, and yet so many of them are not covered by insurance,” he said. “It’s a huge disservice to patients.”

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines